Top Eminent Healthcare Group Limited (6877) has announced an expected consolidated net loss of approximately HK$7.1 million for the year ended 31 December 2025, compared to a net profit of around HK$11.3 million for the year ended 31 December 2024. According to the announcement, the Group’s expanding healthcare business and B2C operations contributed to higher administrative and operating expenses. Additionally, increased professional and legal fees related to corporate transactions and litigation added to overall costs.

The Group also forecasts around HK$4.6 million in other income, down approximately 71% from the previous year’s figure of HK$16.3 million. This decrease is mainly attributed to lower foreign exchange gains and reduced interest-related income. Despite these factors, the Board remains confident in the Group’s longer-term development, citing initiatives such as strategic partnerships, refining product mix, and strengthening digital marketing effectiveness. These measures are expected to gradually improve financial performance once non-recurring costs normalize.

The information is based on preliminary unaudited management accounts and may be subject to adjustment. Final results for the year ended 31 December 2025 are expected to be announced before the end of March 2026.